News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
They will commercialize molnupiravir in the international markets
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Narayanan to lead SeQuent through next phase of consolidation and growth
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Subscribe To Our Newsletter & Stay Updated
